A RET fusion results in the activation of an oncogene that is implicated in the pathogenesis of multiple cancers. 1-4 RET is known to partner with at least 12 different genes, with KIF5B-RET being the most frequently observed RET fusion in NSCLC.5,6
The RET (Rearranged during Transfection) gene encodes a transmembrane receptor tyrosine kinase.7 RET acts as a receptor for Glial cell line-derived neurotrophic Family Ligands (GFL), a group of soluble neurotrophic factors that are highly important during embryogenesis and human development.8,9
†RET fusions also occur in 10-20% of papillary thyroid cancers (PTC)1, 11, 12
‡Medullary thyroid cancer: RET point mutations affect most MTCs1, 3, 12
Lung cancer affects more than 2 million people each year and 85% of these cases occur as non-small cell lung cancer (NSCLC).10 Of those affected by NSCLC, about 2% are associated with RET fusion.1,8 In addition, RET fusions also occur in 10-20% of papillary thyroid cancers (PTC).1,11,12
While RET alterations are rare, new therapies make them highly actionable. With the FDA approval of the RET selective therapies RETEVMO® (selpercatinib) and GAVRETO® (pralsetinib), RET is an essential biomarker to test for in patients with metastatic NSCLC and thyroid cancer. Additionally, with the pan-tumor approval of RETEVMO® (selpercatinib), the detection of RET fusions has expanded treatment options for patients with advanced or metastatic solid tumors. Thus, in order to apply innovative precision medicines, all actionable biomarkers must be tested.
In an example study, out of 10,000 patients, 37% had actionable alterations identified by CGP.14 Given the availability of targeted therapies for RET fusions, the need for molecular characterization within NSCLC has expanded even further.
With a DNA+RNA workflow, CGP enables the simultaneous assessment of the growing number of common and rare driver mutations in a single test. By assessing all biomarkers at once, you may increase chances of finding an actionable alteration.
The landscape of biomarkers in NSCLC is evolving, and testing for RET alterations is increasingly important as new therapies target RET altered tumors. Learn more from Jaclyn Hechtman, MD, in this webinar.
Novel highly selective RET targeted agents have been tested in RET driven NSCLC, advancing targeted treatments. Dig deeper into these discoveries in this infographic.